Thomas A. Davis

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

James M. Schuster, R. K. Lai, Lawrence D. Recht et al. · Neuro-Oncology · 2015 · 417 citations · Full text

Medicine, Oncology, Pharmacology +17

Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification

Shailesh Agarwal, Shawn Loder, Cameron Brownley et al. · Proceedings of the National Academy of Sciences · 2015 · 223 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17

Dopaminergic mechanisms and motor function: Characterization of D-1 and D-2 dopamine receptor interactions

Paolo Barone, Thomas A. Davis, Allen R. Braun et al. · European Journal of Pharmacology · 1986 · 198 citations

Life Sciences, Neuroscience, Pharmacology +16

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

Denise A. Yardley, Robert Weaver, Michelle Melisko et al. · Journal of Clinical Oncology · 2015 · 189 citations · Full text

Medicine, Oncology, Pharmacology +17